Clinical Trial Update: Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement [Phase 2]

View source ↗

Summary

A Phase 2 trial protocol outlines molecular subtype-guided R-CHOP-MTX with optional zanubrutinib for newly diagnosed diffuse large B-cell lymphoma with CNS invo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• METHOTREXATE (METHOTREXATE)
• PREDNISONE (Prednisone)
• R-CHOP
• Rituximab (rituximab)
• Vincristine (vincristine)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Status: NOT_YET_RECRUITING